Levosimendan
- Generic Name
- Levosimendan
- Drug Type
- Small Molecule
- Chemical Formula
- C14H12N6O
- CAS Number
- 141505-33-1
- Unique Ingredient Identifier
- C6T4514L4E
- Background
Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.
- Indication
For short term treatment of acutely decompensated severe chronic heart failure (CHF). Also being investigated for use/treatment in heart disease.
- Associated Conditions
- Acute Decompensated Heart Failure (ADHF), Acute Decompensation of Chronic Heart Failure, Acute Heart Failure (AHF), Chronic Heart Failure (CHF), Acute post-surgical heart failure, Acute, chronic Decompensated Heart Failure, Heart failure post-myocardial infarction, Severe Decompensated Chronic Heart Failure
- Associated Therapies
- Positive cardiac inotropic effect, Intravenous inotropic therapy
Levosimendan in Patients With Impaired Right Ventricular Function Undergoing Cardiac Surgery
- Conditions
- Right Heart FailureOpen-heart Surgery
- Interventions
- Drug: Standard Care
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 40
- Registration Number
- NCT05063370
- Locations
- 🇪🇬
Cardiothoracic Academy, Ain Shams University Hospitals, Cairo, Egypt
Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
- Conditions
- ST Elevation Myocardial InfarctionHeart Failure
- Interventions
- Other: placebo
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2021-08-20
- Lead Sponsor
- Zhijun Sun
- Target Recruit Count
- 500
- Registration Number
- NCT04970238
- Locations
- 🇨🇳
Shengjing Hospital, Shenyang, Liaoning, China
Effect of Levosimendan on miRNAs Regulation in the Failing Hearts
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT04950569
- Locations
- 🇨🇳
Tongji Hospital, Wuhan, Hubei, China
Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
- Conditions
- Cardiorenal SyndromeAcute Kidney FailureCardiogenic Shock
- Interventions
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- University of Zurich
- Target Recruit Count
- 43
- Registration Number
- NCT04917497
LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients
- Conditions
- Cardiogenic ShockExtracorporeal Membrane Oxygenation Complication
- Interventions
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 206
- Registration Number
- NCT04728932
- Locations
- 🇫🇷
Hôpital du Haut-Lévêque, Pessac, Bordeaux, France
🇫🇷Hôpital Pitié Salpêtrière, Paris, France
🇫🇷Hôpital Européen Georges Pompidou, Paris, France
Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents
- Conditions
- Cardiac FailureHypertension, PulmonaryPulmonary Vascular Resistance Abnormality
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Aretaieion University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04718350
- Locations
- 🇬🇷
Onassis Cardiac Surgery Center, Athens, Greece
Levosimendan In Ambulatory Heart Failure Patients
- Conditions
- Heart Failure New York Heart Association Class IIIHeart Failure New York Heart Association Class IVHeart Failure With Reduced Ejection FractionHeart Failure, Systolic
- Interventions
- Other: Placebo
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Medical University of Bialystok
- Target Recruit Count
- 70
- Registration Number
- NCT04705337
- Locations
- 🇵🇱
University Hospital of Lord's Transfiguration, Poznań, Poland
🇵🇱Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego, Warszawa, Poland
🇵🇱Medical University of Bialystok Clinical Hospital, Bialystok, Poland
Levosimendan Administration in Pulmonary Hypertension
- Conditions
- Cardiac FailureHypertension, PulmonaryPulmonary Vascular Resistance Abnormality
- Interventions
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Aretaieion University Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT04599816
- Locations
- 🇬🇷
Onassis Cardiac Surgery Center, Athens, Greece
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
- Conditions
- Heart FailureEffect of DrugCardiac EventInotropic AgentsSafety IssuesTranscatheter Aortic Valve ReplacementAortic Valve Stenosis
- Interventions
- Other: Placebo
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 124
- Registration Number
- NCT04573049
- Locations
- 🇨🇳
Jianhui Wang, Beijing, Beijing, China
Levosimendan Versus Combination With Magnesium Sulphate on Spine Protection by NIRS in Infants Undergoing Coarctectomy
- Conditions
- Aortic Coarctation
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Dalia Saad Abd-El Kader
- Target Recruit Count
- 40
- Registration Number
- NCT04330755
- Locations
- 🇪🇬
Sara ABD El-Salam, Cairo, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.